If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic ...

American institutions have contributed to and benefited from membership in WHO.” Calling U.S. foreign aid “not aligned with American interests,” Trump issued an order to pause foreign ...

As President Donald Trump takes office and ushers in a new era of U.S. global development engagement, what should U.S. foreign aid partners expect? As Donald Trump takes office for a second time ...

But with Hamas asserting its grip on Gaza, questions remain about how aid is distributed. By Hiba Yazbek reporting from Jerusalem The amount of humanitarian aid entering Gaza surged dramatically ...

in additional military aid for Ukraine. "To be honest, it hurts me a lot," she said without mentioning the chancellor's name in an interview with Politico released on Friday, adding that for some ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 1.72% to $416.96 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.21 ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...

It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could move up or down but typically not enough to matter all that much. However, there are ...

The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...